Tocilizumab and Systemic Corticosteroids in the Management of Patients with COVID-19: A Systematic Review and Meta-Analysis
Open Access
- 1 September 2021
- journal article
- review article
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 110, 320-329
Abstract
No abstract availableKeywords
Funding Information
- Deanship of Scientific Research, King Saud University
- King Saud University
This publication has 45 references indexed in Scilit:
- Clinical Characteristics of Coronavirus Disease 2019 in ChinaNew England Journal of Medicine, 2020
- COVID-19: consider cytokine storm syndromes and immunosuppressionThe Lancet, 2020
- Risks of non-vaccinationMedecine Et Maladies Infectieuses, 2020
- Cytokine release syndromeJournal for ImmunoTherapy of Cancer, 2018
- Low immunogenicity of tocilizumab in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2017
- Toxicities of chimeric antigen receptor T cells: recognition and managementBlood, 2016
- Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE studyAnnals of the Rheumatic Diseases, 2012
- What's the Relative Risk?JAMA, 1998
- Lucian A selection. Ed. and trM.D. Macleod. Warminster: Aris and Phillips, 1991. Pp. iv + 316. £35.00 (bound), £12.50 (paper).The Journal of Hellenic Studies, 1993
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986